**GHIT Fund Hit-to-Lead Platform**

**RFP Intent to Apply Form**

**Reference Number: GHIT-RFP-HTLP-2025-002**

**Please submit the Intent to Apply (ITA) form via Editorial Manager® for Hit-to-Lead Platform (**[**https://www.editorialmanager.com/ghitfund/**](https://www.editorialmanager.com/ghitfund/)**) by 10:00 a.m. JST on August 1, 2025.**Please do NOT submit documents other than the ITA form to the GHIT Fund.  
Applicants who submit the ITA form will receive a confirmation email.  
The GHIT Fund Management Team will then perform an initial partnership and scope eligibility assessment.   
**Only eligible applicants will be invited to submit full proposal and will receive instructions to access the proposal templates from the GHIT Fund**.

Should applicants have RFP-related questions, please send an email to [RFPResponse@ghitfund.org](mailto:RFPResponse@ghitfund.org).

Please also refer to the Frequently Asked Questions (FAQ) page on the GHIT website: <https://www.ghitfund.org/applyforfunding/investmentfaq/en>.

**Table of Contents**

[1. History of Applying for Funding to the GHIT Fund 2](#_Toc199332200)

[2. Project Title 2](#_Toc199332201)

[3. Target Disease 2](#_Toc199332202)

[4. Partnership and Role/Responsibility 2](#_Toc199332203)

[5. Research/Project Summary 3](#_Toc199332204)

[5.1 Project Overview (200-word limit) 3](#_Toc199332205)

[5.2 Independent Scientific Review 3](#_Toc199332206)

[5.3 Global Health Need and Impact (200-word limit) 3](#_Toc199332207)

[6. Project Budget 4](#_Toc199332208)

[7. Compliance Checklist 4](#_Toc199332209)

[8. Agreement/Signature 5](#_Toc199332210)

# History of Applying for Funding to the GHIT Fund

Please provide the project ID number for programs **related to this application**.Please specify if this is a new application or a continuation of a project previously funded by the GHIT Fund.

*Insert Project ID Here*

*Example: Continuation of T201X-10X (Awarded) and resubmission of T202X-10X (not awarded)*

# Project Title

*Insert Project Title Here*

# Target Disease

*Please check all that apply*

|  |  |
| --- | --- |
| Disease | |
| Malaria  Tuberculosis  Chagas Disease  Schistosomiasis | Viral infectious diseases with pandemic potential\*  \*Please specify  Ebola virus (*Filoviridae*)  Marburg virus (*Filoviridae*)  Lassa fever (*Arenaviridae*)  Nipah virus (*Paramyxoviridae*)  Henipa virus (*Paramyxoviridae*)  Rift Valley fever (*Bunyaviridae*)  Zika (*Flaviviridae*)  Chikungunya (*Togaviridae*)  Rabies (*Rhabdoviridae*)  Others ( ) |

# Partnership and Role/Responsibility

**The partnership consists of the following organizations** (Add columns if your partnership consists of more than three organizations).

The GHIT Fund **requires one of the three PDPs below to be included as a Collaboration Partner in HTLP projects.** A partnership with one of the below PDPs must be established at the time of ITA form submission.

* **Medicines for Malaria Venture (MMV)**
* **Drugs for Neglected Diseases Initiative (DNDi)**
* **TB Alliance**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Designated Development Partner/**  **Collaboration Partner 1** | **Collaboration**  **Partner 2** | **Collaboration**  **Partner 3** |
| Organization Name |  |  |  |
| Organization Type  (e.g., PDP, pharma company, academic institution) |  |  |  |
| Organization Status | ☐ Japanese  ☐ Non-Japanese  Please specify the country below.  \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | ☐ Japanese  ☐ Non-Japanese  Please specify the country below.  \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | ☐ Japanese  ☐ Non-Japanese  Please specify the country below.  \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| Organization Address and Phone Number |  |  |  |
| Organization Webpage |  |  |  |
| Lead PI (name and job title) |  |  |  |
| Contact Details (email and phone) |  |  |  |
| Role and Responsibility |  |  |  |

# Research/Project Summary

## 5.1 Project Overview (200-word limit)

Provide an overview of the **two-year project** that you are applying for funding from the GHIT Fund, including milestones and activities, and the expected outcome/deliverables at the end of the project.

|  |
| --- |
| *Such as What, Why, Who, When, How, How Much, Milestones, Activities, Deliverables, etc.* |

## 5.2 Independent Scientific Review

If the proposed project has already been reviewed by an established independent scientific or technical advisory committee (such as those established by PDPs), please summarize here.

|  |
| --- |
|  |

## 5.3 Global Health Need and Impact (200-word limit)

What makes this project unique in addressing global needs and making a significant impact in the short or long term?

|  |
| --- |
|  |

# Project Budget

Please provide the approximate amount of funding in Japanese Yen required to support the proposed project (**capital costs should be excluded**). Please provide the currency exchange rate used to calculate the total budget in Japanese Yen, if applicable.

|  |
| --- |
|  |

# Compliance Checklist

Please answer the following questions regarding the Designated Development Partner, Collaboration Partner(s), and Principal Investigators who will be involved in the project proposed in this application (“Project”).  Please mark ‘Yes’ or ‘No’ and provide explanations as needed.  Please note that your answers in this section will be taken into account by the GHIT Fund as in its decision on your application.

|  |  |
| --- | --- |
| 1. Are there any pending or threatened civil, criminal, administrative, or regulatory proceedings, actions, suits, or investigations (either as a plaintiff or a defendant) that could have an effect on the Project? | ​​☐ No  ​​☐​ Yes – Please explain: |
| 1. Are sufficient measures in place to ensure that the project is implemented, controlled, managed, and monitored in compliance with all applicable ethical, legal, regulatory, and safety rules and requirements, including applicable international, national, local, industry, and institutional standards? | ​​☐​ No  ​​☐​ Yes – Please explain: |
| 1. Are sufficient measures in place to prevent each of the following?  * Research Misconduct[[1]](#footnote-2) * Misuse, misappropriation, or other inappropriate use of grants, donations, contributions, or subsidies[[2]](#footnote-3) | ​​☐​ No  ​​☐​ Yes – Please explain: |
| 1. Please confirm that, to the best of their knowledge, the Designated Development Partner, Collaboration Partner(s), and/or Principal Investigator(s) have not, directly or indirectly supported or promoted, and will use reasonable efforts to ensure that they do not directly or indirectly support or promote, terrorist, criminal, or anti-social activities or related training, or money laundering. | ​​☐​ Confirm  ​​☐​ Do not certify |
| 1. Please confirm that the Designated Development Partner, Collaboration Partner(s), and/or Principal Investigator(s) have never taken any action to directly or indirectly offer, pay, promise to pay, or authorize or approve the payment or giving of money, property, gifts, or anything else of value, directly or indirectly, to any government official in Japan or in any other jurisdiction or any official of any public international organization for the purpose of  influence official action or securing an improper advantage. | ​​☐​ Confirm  ​​☐​ Do not confirm |
| 1. Please read and acknowledge the “Award Administration and Conditions” described in the RFP. | ​​☐​ Acknowledge  ​​☐​ Do not acknowledge |

# Agreement/Signature

This Intent to Apply form is submitted by:

|  |  |
| --- | --- |
| Name:  Title:  Organization:  Date: |  |
| **Agreement**  We hereby agree that the above information is accurate and true. We understand that any false information provided may result in the revocation of the proposal submitted.  (Signature) | |

[End of Document]

1. *In the “Guidelines for Responding to Research Misconduct (Approved by the Ministry of Education, Culture, Sports, Science and Technology on August 26, 2014)”, each of the following acts is defined as specific research misconduct:*

   *(1) Fabrication: making up data or research results, etc.*

   *(2) Falsification: manipulating research materials, equipment, or procedures to alter data or results obtained from research activities* [↑](#footnote-ref-2)
2. *“Misuse” shall mean the use of such funds for purposes other than those originally intended or agreed upon, whether intentionally or through gross negligence.* [↑](#footnote-ref-3)